Polynovo Limited (ASX:PNV): Why This Under-the-Radar ASX Stock Could Be One to Watch in September

Sonal Goyal

02 September 2026 05:28 PM AEST

Polynovo Limited (ASX:PNV): Why This Under-the-Radar ASX Stock Could Be One to Watch in September

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

PolyNovo is a medical-device company — a widely followed name rather than a truly obscure one — whose NovoSorb technology is used in wound care and surgical reconstruction, most notably its Biodegradable Temporising Matrix for treating severe burns and complex wounds. With a large United States market and an expanding product range, PolyNovo has been a favourite among Australian medical-device investors.

For FY26, PolyNovo (ASX:PNV) reported record Revenue of around A$150 million and turned free-cash-flow positive after record United States sales, a significant milestone for a company that has been investing heavily to grow. The result reflected continued commercial expansion of its NovoSorb wound-care portfolio, particularly in the United States.

What Could Drive the Shares Next?

Catalysts include continued growth in United States and international sales, expansion of the NovoSorb product range into new indications, further improvement in cash flow, and any new regulatory clearances. Evidence that the Business can keep compounding revenue while generating cash would support the shares.

Sustained record sales with positive free Cash Flow would be the clearest positive signal.

Risks Investors Should Watch

PolyNovo is exposed to the pace of adoption of its products in the competitive United States wound-care and surgical markets, and to reimbursement dynamics. Growth expectations are high, so any slowdown can move the shares.

Competition, the pace of product-range expansion, and execution in international markets are additional considerations.

Investor Takeaway

PolyNovo delivered record FY26 revenue of around A$150 million and turned free-cash-flow positive after record United States sales, marking a financial inflection. Whether it warrants a September watch depends on sustaining sales growth while generating cash. United States sales, product expansion and cash flow are the things to watch.

FAQs

Q: What revenue milestone did PolyNovo reach in FY26?

A: PolyNovo reported record revenue of around A$150 million, driven by record United States sales of its NovoSorb wound-care portfolio.

Q: Did PolyNovo achieve positive cash flow in FY26?

A: Yes, PolyNovo turned free-cash-flow positive for the first time, marking a significant financial inflection for the company.

Q: What is PolyNovo's main product technology?

A: PolyNovo's NovoSorb technology, most notably its Biodegradable Temporising Matrix, is used in wound care and surgical reconstruction, including treating severe burns and complex wounds.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.